Compare ACU & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACU | SPRO |
|---|---|---|
| Founded | 1867 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.0M | 136.7M |
| IPO Year | N/A | 2017 |
| Metric | ACU | SPRO |
|---|---|---|
| Price | $40.58 | $2.29 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 8.1K | ★ 280.4K |
| Earning Date | 10-21-2025 | 11-13-2025 |
| Dividend Yield | ★ 1.58% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.45 | N/A |
| Revenue | ★ $194,960,991.00 | $40,549,000.00 |
| Revenue This Year | $2.19 | N/A |
| Revenue Next Year | $4.55 | N/A |
| P/E Ratio | $16.56 | ★ N/A |
| Revenue Growth | ★ 2.35 | N/A |
| 52 Week Low | $34.35 | $0.51 |
| 52 Week High | $45.25 | $3.22 |
| Indicator | ACU | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 62.38 | 47.60 |
| Support Level | $40.78 | $2.26 |
| Resistance Level | $42.33 | $2.42 |
| Average True Range (ATR) | 1.37 | 0.08 |
| MACD | 0.22 | 0.00 |
| Stochastic Oscillator | 78.40 | 27.15 |
Acme United Corp is a supplier of first aid and medical products and cutting technology to the school, home, office, hardware, sporting goods, and industrial markets. Its principal products sold across all segments are first aid kits and medical products, scissors, shears, knives, rulers, pencil sharpeners, and sharpening tools. The Company sells its products to mass market and e-commerce retailers, industrial distributors, wholesale, contract, and retail stationery distributors, office supply superstores, sporting goods stores, and hardware chains. The Company's reportable business segments consist of the United States, Canada, and Europe, out of which the majority of the company's revenue is derived from the United States.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.